Founded with a mission to revolutionize ophthalmic drug delivery, Vitranu focuses on addressing the unmet need for sustained and controllable medication release in eye care. Their core product, the Tunable Extended-Release Capsule (TERC™), leverages electrospinning technology to provide a prolonged and adjustable release of biologic pharmaceuticals. This innovation aims to reduce the frequency of eye injections, thereby improving patient compliance and outcomes, particularly for conditions like macular degeneration.
Vitranu has garnered attention from notable figures in the biotech and ophthalmology sectors, attracting investment and advisory support from industry leaders. The company has achieved significant milestones, including successful preclinical trials demonstrating the efficacy and safety of their TERC™ technology. By potentially reducing the number of necessary eye injections, Vitranu's impact extends to enhancing the quality of life for millions of patients globally, addressing a critical gap in current ophthalmic treatments.
